oncodaily - On May 14, 2026, AstraZeneca announced positive high-level results from a planned interim analysis of the Phase III VOLGA trial, evaluating perioperative Imfinzi with or without Imjudo in combination with […]
AI Summary: Phase III VOLGA trial results reveal that combining durvalumab (Imfinzi) with neoadjuvant enfortumab vedotin improved survival outcomes in muscle‑invasive bladder cancer. Investigators and industry voices highlight potential practice-changing implications for perioperative therapy, while stakeholders weigh regulatory filings and integration into treatment guidelines. Clinicians will want full datasets and toxicity details.
Datroway secures regulatory approvals in breast cancer across US and EU / 8 days
FDA clears first targeted therapy for ultra-rare NRG1-driven cholangiocarcinoma / 20 days
FDA grants early access to experimental pancreatic cancer drug / 29 days
FDA approves relacorilant plus nab‑paclitaxel for resistant ovarian cancers / 7 wks
FDA flags misleading cancer drug claims tied to biotech billionaire / 2 months
FDA clears pivekimab sunirine (Decnupaz) as first BPDCN ADC / 46 hrs
FDA to revisit Atara/Pierre Fabre cell therapy approval for rare lymphoma / 22 days
StackHealth RSS

StackHealth Time Machine
NorthFeed Inc. Terms and Conditions / Privacy Policy
Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.